Diabetic macular oedema (DMO) is the most frequent cause of vision loss in patients affected by diabetes mellitus, and has a remarkable effect on public health. The treatment with focal/grid laser photocoagulation was considered in the past decades as the standard of care, but the recent advent of new pharmacological approaches, based on the use of intravitreal anti-vascular endothelial growth factor (anti-VEGF), has completely revolutionised the management of DMO. The most important molecule of this class of drugs is represented by ranibizumab, which has been clinically supported by several randomised clinical trials. The present review aims at providing a comprehensive summary of the most important investigations regarding the ranibizumab treatment of DMO.
(Ig)-G1, functioning as a soluble decoy receptor or all VEGF-A isoforms, with a higher affinity (140 times stronger) and longer half-life in comparison to all the others anti-VEGF substances.
Corticosteroids reduce the breakdown of the blood-retinal barrier, have anti-inflammatory and anti-angiogenic properties and experimentally have been disclosed to down-regulate VEGF production; triamcinolone acetonide, fluocinolone and dexamethasone are the three most used steroidal molecules in DMO management. 14 The aim of this article is to review the role of ranibizumab in the management of DMO, focusing on the most important trials that have proved its efficacy and safety.
Ranibizumab
Ranibizumab (Lucentis; Genentech USA Inc., San Francisco, CA, US/ Novartis Ophthalmics, Basel, Switzerland) is a Fab derived from bevacizumab, but it is smaller and specifically designed for use in the eye. 15 In the third year, the study design allowed for patients in the sham group to cross-over and receive monthly IVR; however, delayed treatment in these patients resulted in the lower functional recovery in terms of patients originally randomised to IVR. 16 The RESOLVE study, a 12-month randomised, double-masked, multicentre, phase II study, investigated the most effective concentration of ranibizumab through comparing 151 eyes with DMO randomly assigned to two different groups of IVR (0.3 or 0.5 mg; n=51 each) or sham (n=49).
The treatment schedule comprised three consecutive monthly injections, followed by repeated treatment or rescue laser photocoagulation in case of refractory oedema. At 1-year follow-up, mean best-corrected VA (BCVA) improved from baseline by 11.8 letters and 8.8 letters in the 0.3 or 0.5 mg group, respectively; pooled data (including both dosing regimens) showed a total gain of 10.3 letters from baseline. BCVA declined by 1.4 letters with sham and only 4.9 % of IVR patients required rescue laser compared with 34.7 % of sham.
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Ranibizumab plus Laser Combination Treatment
Combination treatment has been recently analysed in a meta-analysis pooling data from seven RCTs (see Table 1 ) and 1,749 patients (394 patients in the IVR group, 642 in the IVR + laser group and 713 in the laser group). 18 One trial (the LUCIDATE study) was a single-centre trial, while the others were all multicentre trials. IVR and IVR + laser were superior to laser monotherapy in the mean change of BCVA and central retinal thickness (CRT) from baseline. The pooled relative risk (RR) comparing the proportions of patients with at least 15 letters improvement were also in favour of IVR and IVR + laser (RR = 2.94; p<0.00001 and RR = 2.04; p<0.00001); same results for at least 15 letters deterioration (RR = 0.21; p=0.01 and RR = 0.52; p=0.03, respectively). There were no significant differences between IVR and IVR + laser for any of the parameters.
This analysis showed that the mean number of ranibizumab tended to be less in IVR + laser arm in terms of IVR monotherapy (6.8 versus 7.0 injections in the RESTORE study at 1 year and 3.3 versus 5.4 injections in the READ-2 study at 3 years).
In detail, the READ-2 was a phase II, prospective, randomised clinical trial conducted at 14 sites in the US, designed to compare IVR monotherapy with combination therapy with focal/grid laser in patients with DMO. One hundred and twenty-six patients were randomised to receive 0.5 mg IVR (n=42), focal/grid laser photocoagulation (n=42) or a combination of 0.5 mg of ranibizumab and focal/grid laser (n=42). 19 Ranibizumab was administered at baseline and at months 1, 3, 5, and focal/grid laser was administered at baseline and again at month 3 only if central subfoveal thickness (CST) was ≥250 μm. The change in BCVA at month 6 compared with baseline in the IVR monotherapy group was higher (+7.24 letters) than the laser monotherapy (-0.43 letters) and combination (+3.8 letters) groups. At month 24, the 101 patients remained in the study showed a mean BCVA improvement of 7.7 letters in the IVR-only group The REVEAL study, a 12-month, double-masked, multicentre, lasercontrolled, phase III study followed the same design, randomising 396 Asian patients to ranibizumab + sham laser (n=133), ranibizumab + active laser (n=132) or sham injection + active laser (n=131). Ranibizumab/ sham injections were administered on day 1 and continued monthly. 
Regimen of Treatment
As far as it regards the correct regimen of treatment, two recent phase IIIb multicentre studies (RETAIN and RELIGHT) have respectively investigated ranibizumab schedule on the bases of a treat-and-extend (TE) regimen and a bimonthly follow-up with PRN regimen.
RETAIN, a 24-month single-masked study, explored the non-inferiority/ superiority of a TE regimen, with/without laser, to a PRN regimen in patients with visual impairment due to DMO. 26 Three hundred and seventy-two eyes were randomised to TE ranibizumab + laser (n=121), TE ranibizumab (n=128) or PRN ranibizumab (n=123). In phase A, all patients received monthly ranibizumab until VA stability. In phase B, the therapy-free interval was incrementally extended by 1 month (up to 3) in VA-stable patients in TE groups. PRN patients were monthly visited in phase B. Both TE groups were non-inferior to PRN based on mean BCVA change from baseline to month 12 (+5.9 and +6.1 versus +6. 
Safety
Globally, these trials have showed that patients randomised to ranibizumab were more likely to experience improvements in DR severity as measured by ETDRS retinopathy severity scale and less likely to develop proliferative DR. However, IVR injections have shorter duration of action and higher recurrence rate of the disease compared with laser treatment, therefore requiring more frequent treatments; higher frequency of treatments automatically exposes patient to a higher rate of side effects, connected to both surgical procedure and systemic exposure to the drug. The most common side effects connected to the surgical procedure are conjunctival haemorrhage, eye pain, vitreous floaters, increased intraocular pressure and intraocular inflammation; more severe complications, including endophthalmitis, retinal tears and holes and vitreous haemorrhage, occurred with an incidence rate of less than 1 %. 28 Patients with DMO and co-existing proliferative DR have showed an increased risk of vitreal fibrosis and consequent tractional retinal detachment.
Although anti-VEGF therapy has shown a favourable tolerability profile in patients with diabetes, research has shown that a little amount of intravitreal anti-VEGF drugs pass into systemic circulation, and may increase the risk of non-ocular adverse events, including thromboembolic events (TEE) and hypertension (HTN). Different
RCTs have tried to evaluate anti-VEGF molecules in terms of relative efficacy and systemic safety. 29, 30 Recently, the 2-year Comparison of the AMD Treatments Trial (CATT) 31 and the Age-related Choroidal Neovascularization Trial (IVAN) 32 have performed a head-to-head comparison between ranibizumab and bevacizumab in treatment of age-related macular degeneration. In IVAN, there were more atherothrombotic events and heart failure with ranibizumab. In CATT, adverse events (including infections, palpitations and accidents) were more frequent with bevacizumab than ranibizumab (24 % versus 19 % at 1 year, and 40 % versus 32 % at 2 years). The costs of bevacizumab are 20 to 40-fold lower than those of ranibizumab, and it has been estimated that in each European country, the costs of ranibizumab treatment of DMO would be around 10-15 million euros higher than treatment with bevacizumab. ranibizumab for 1 year. 35 They observed a significant BCVA improvement in both groups at all study visits, but this improvement was significantly greater in the ranibizumab group at week 8 and 32. There was no significant difference in decrease in CRT. The mean number of injections was significantly higher in the bevacizumab group (9.84) than in the ranibizumab group (7.67).
Trial NCT01610557, a double blind comparison of ranibizumab as monotherapy and ranibizumab and bevacizumab consecutively, is ongoing.
Ranibizumab versus Bevacizumab versus Aflibercept
Recently, a multicentre, randomised clinical trial (PROTOCOL T), sponsored by DRCR.net, has been published comparing the relative efficacy and safety of ranibizumab in the treatment of DMO with aflibercept and bevacizumab. 36 Six hundred and sixty adults with DMO were randomly assigned to receive 2.0 mg aflibercept (n=224), 1.25 mg bevacizumab (n=218) or 0.3 mg ranibizumab (n=218). The study drugs were administered every 4 weeks, according to a protocol-specified algorithm. Laser photocoagulation therapy (focal, grid or both) was initiated at or after the 24-week visit for persistent diabetic macular oedema, defined on the basis of protocol-specified criteria.
The primary outcome was the mean change in BCVA at 1 year: it turned out that all ranibizumab, aflibercept and bevacizumab improved VA in eyes with centre-involving DMO, but the improvement was greater with aflibercept than with the other two drugs (+13.3 with aflibercept, +9.7 with bevacizumab and +11.2 letters with ranibizumab from baseline; p<0.001 for aflibercept versus bevacizumab and p=0.03 for aflibercept versus ranibizumab). However, this improvement was not clinically meaningful because the difference was driven by the eyes with worse VA at baseline, and the relative effect depended on baseline VA.
In detail, when the initial BCVA was comprised in the 78 to 69 range (51 % of participants), the mean improvement was +8.0 with aflibercept, +7.5 with bevacizumab, and +8.3 with ranibizumab (p>0.50 for each pairwise comparison). When the initial BCVA was less than 69, the mean improvement was 18.9 with aflibercept, 11.8 with bevacizumab and 14.2 with ranibizumab (p<0.001 for aflibercept versus bevacizumab, p=0.003 for aflibercept versus ranibizumab and p=0.21 for ranibizumab versus bevacizumab).
The median number of injections using the protocol-specified retreatment regimen was one fewer in patients treated with aflibercept compared with bevacizumab and ranibizumab: it was nine in the aflibercept, 10 in the bevacizumab and 10 in the ranibizumab group (p=0.045 for overall comparison).
Patients in the aflibercept group received fewer criteria-based macular laser treatments than those treated with bevacizumab and ranibizumab.
There were no significant differences among the study groups in the rates of serious adverse events (p=0.40), hospitalisation (p=0.51), death (p=0.72) or major cardiovascular events (p=0.56). In conclusion, the ranibizumab approach is a major breakthrough in the treatment of DMO; a unified accepted protocol of treatment has not been found, and an individualised patient-based approach is rather preferred.
Conclusion
New trials are required in order to answer these clinical open questions. n
